Malaria Diagnostics Market - Share Analysis (2024–2032)

Malaria Diagnostics Market Synopsis:

Malaria Diagnostics Market Size Was Valued at USD 0.77 Billion in 2023, and is Projected to Reach USD 1.31 Billion by 2032, Growing at a CAGR of 5.4 % From 2024-2032.

The Malaria Diagnostics Market comprises a vast variety of products aimed at diagnosing malaria, which is still a critical problem in tropical and subtropical countries. The market features basic diagnosis techniques including microscopy and quick diagnostic tests (RDTs) together with sophisticated molecular techniques including PCR and LAMP as diagnosis techniques continue to evolve. These technologies are important for diagnosing malaria, and distinguishing between different species of Plasmodium, detecting low-level infections, and for malaria drug resistance surveillance. Market growth is predominantly anticipated by the constant increase in malaria cases, especially in sub-Saharan Africa, the growing investment in healthcare in high-risk areas, and the emerging need for faster and more efficient diagnostic tools. The use of diagnostic devices with more decentralized and personalized medical diagnosis through technologies such as point-of-care, self-testing, mobile-health, among others, are others factors that has helped to increase the demand for diagnostic devices across the regions that are hard to reach, or they are poorly equipped. Because malaria control and its eventual eradication remain global priorities, malaria diagnosis serves as an essential modality in the timely management, monitoring, and scheming of new therapies and vaccines against malaria episodes.

The Malaria Diagnostics Market is perhaps one of the most important markets of the global healthcare market due to the global importance of this disease. Malaria remains a major disease risk in sub-Saharan Africa, South East Asia and some Latin American countries and is still a cause of high mortality and morbidity. World Health Organization reported that in 2022, there where 247 million cases and 619000 deaths due to malaria worldwide and highlighting the importance of accurate, rapid, and effective diagnosis.

Malaria diagnostics are available through different methods which include microscopy which is the benchmark in malaria diagnostic followed by RDTs, PCR and LAMP. The use and integration of these technologies is propelled by the growing need for Point of Care (POC) diagnostic that can be deployed in remote and limited resource environments to provide accurate results in a shorter time. Efforts to lessen reliance on malaria rapid diagnostic tests include new methods that are more sensitive and cost effective, can detect low-parasite infections and drug resistance. Also, there is growth in self-testing kits and, mobile health that has helped in extending diagnostics especially in areas of low market access.

Malaria Diagnostics Market Trend Analysis:

Shift Toward Point-of-Care (POC) Testing

• Among all the transforming factors, rise of point of care testing for malaria diagnostics another key factor for transformation experienced in this market. Easy to carry and perform at the bedside and also does not require a laboratory, capillary malaria diagnosis provides immediate results. This is especially so because most malaria endemic areas experience poor health systems or in most cases congested and centralized hospitals. RDT is one of the most utilized form of POC tests and integration of RDT has transformed the testing done for malaria by being simple, faster and more reliable and takes less than 30 minutes. These tests identify malaria antigens like HRP2 or pLDH from a patient’s blood sample, therefore helping carers, including community health staff in butiuti, make early and accurate diagnosis. Some of the benefits for using RDTs include; the fact that they are cheap, user-friendly, and does not require a lot of training to perform a test. Consequently, POC diagnostics have now been integrated as critical lasts-mile tools for national malaria control and elimination efforts, particularly in remote and rural settings where laboratory human resources for diagnostics are hardly available.
• In addition, routine and rapid POC testing continues to increment the malaria control and elimination agenda by decreasing lag time to the actual diagnosis and testing which enables the patients to receive their rightful treatment without much delay. This close follow up is important in containing spread of the disease and reducing severity of some complications especially from P.falciparum which is the most pathogenic of all malaria parasites. The recent addition of mobile health integration has added another positive influence to POC testing. With the adoption of MH as an integral component of diagnostic tools, the results can be instantly sent to central health databases or other offsite healthcare practitioners enhancing the efficiency of surveillance, tracking, and reporting at the actual time. Moreover, there have emerged newer technologies for example, the Loop-Mediated Isothermal Amplification (LAMP) is a more sensitive molecular diagnostic that can replace microscopy in POC. Despite the continued predominance of the RDT segment, more advanced innovations in biosensors, micro fluidic systems and nanotechnology will further advance future POC malaria diagnostics as much faster and more portable means. As with any change in practice or care model, it is not without its own set of problems, such as quality concerns, supply chain issues, or concerns of accessibility through costs – Regardless, the move towards POC testing will certainly continue to be helpful in proactive steps towards detecting malaria and aiding in further eradication efforts.

Integration of Mobile Health (mHealth) Technologies

• mHealth continues to find its place as one of the Malaria Diagnostics Market strategic actions to increase the diagnosis rate of malaria apart from being a quick and inexpensive option to reach out to areas that were initially not accessible at all. Mobile devices can offer the mechanism of instant transmission of the malaria diagnostic result to the central health system or to health care workers in an away station. This enhances fast decision making, involve professionals at distant centres as well as fastens treatment, crucial in malaria dominated zones. More so, mobile health technologies can be used in real time epidemiological surveillance, case reporting on malaria useful in identifying trends/epidemic and designing intervention. The use of mobile applications for data collection for global health initiatives may also enhance reliability of monitoring and controlling malaria.
• Also, that the adoption of mHealth solutions in the diagnosis of malaria is relatively cheap and eviction. Mobile diagnostic attachment to smart phones or other portable like small easy to use diagnostic tools by the health care workers in far areas with returns of results without complicated diagnosis. This progresses to the extent that the kind of technologies that enable it can work in conjunction with artificial intelligence (AI) that is typical to reduce the mistakes. Besides, constant mHealth can improve the interaction with patients by occasionally notifying the patient about visits, medications, and precautions with regards to early detection of illnesses to minimize the amount of delay in receiving treatment. Mobile health or mHealth has potential in the fight against malaria because of the ever-increasing mobile phone usage in the developing world which enables delivery of timely diagnosis and real time monitoring to address basic shortfalls in the global health system.

Malaria Diagnostics Market Segment Analysis:

Malaria Diagnostics Market Segmented on the basis of Type, Application, End User, and Region

By Type, Rapid Diagnostic Tests (RDTs) segment is expected to dominate the market during the forecast period

• Out of all the segments, the Malaria Diagnostics Market is expected to be led by the Rapid Diagnostic Tests (RDTs) due to factors such as feasibility of use, relatively low cost, and rapidness. In the regions that lack optimum laboratory facilities and equipment, RDTs are easy to use, fast, accurate, safe and do not require technical expertise. The assessments provide results within half an hour, making them great forPoint-of-Care (POC) diagnostic tools in areas with inadequate resources. Since malaria is found mainly in regions of low health infrastructure, the need for RDTs is increasing because they are cheaper, with the goal of increasing early detection rate, decreasing the time spent on diagnosing and timely treatment. This factor has become central to their market popularity because of their ubiquity in malaria-active regions and remote countryside.
• In addition, malaria elimination and control agendas worldwide are speeding up the utilization of RDTs. They are easy to carry out, and their use does not necessitate formal training of the diagnostic nature, leaving them open to use by community health workers and other healthcare practitioners. Notably, RDTs are cheaper to obtain than PCR tests or microscopy making them more preferable, especially in developing countries where the challenges of the budget constraint are real. Moreover, consistent emphasis on quick diagnosis in an attempt to limit the transmission of malaria is also likely to make the RDT segment dominate the global market over the forecast period due to rising trends in premeditated malaria prevention and enhanced disease management in affected regions.

By Application, Clinical Diagnostics segment expected to held the largest share

• It was observed that the Clinical Diagnostics segment accounted for the largest share of the Malaria Diagnostics Market during the forecast period because of its use in accurately diagnosing malaria and administering appropriate treatment when it is contracted in healthcare centres. Severe malaria is one of the complications of early malaria and therefore timely diagnosis is very important for treatment. From hospitals, clinics and diagnostic laboratories, early and accurate detection is needed most especially for effective patient care management. As malaria is characterized by high morbidity and mortality, clinical diagnostics are still essential in malaria control especially in malaria endemic countries. It is becoming extremely important to do malaria testing rapidly and accurately using diagnostic tools such as RDTs, microscopy, PCR, and LAMP so that correct interventions can be started. This segment is expected to hold the largest share of the market due to increasing focus on diagnostics and primary care along with valid concerns of avoiding disease load in certain populations.
• Furthermore, the growing thrust towards malaria elimination and diseases management in the experienced countries and among travelers also nurture the global clinical diagnostics demand. As mentioned previously, clinical laboratories employ both Rapid Diagnostic Tests (RDTs) and molecular diagnostic methods such as PCR for confirmation of the parasite and determination of the active infection as well as for Plasmodium species and drug-resistant strains. Also, diagnostic tools are being integrated with the digital health solutions that include mHealth to improves the accuracy of the diagnosis of malaria as well as monitor the patients’ progress at clinical level. As the global investments in healthcare are on the rise and as there is growing emphasis on extending healthcare to the resource challenged regions, the clinical diagnostics segment has all the possibilities of realizing a steady growth in the future. This growth will be as a result of the increased need to diagnose malaria more effectively and due to the sustained focus on malaria as a major public health concern by national governments, NGOs and WHO.

Malaria Diagnostics Market Regional Insights:

North America is Expected to Dominate the Market Over the Forecast period

• North America is anticipated to lead Malaria Diagnostics Market in the forecast period based on various parameters like growing focus toward better health care infrastructure, developing advanced diagnostic technique, and persistent effort toward malaria control across the malaria endemic countries. Malaria is exotic in North American countries, however the region remains strategically important for financing, research, innovation and global health policy. Many profit and non-profit organizations in the North American region especially within the US and Canada are key players in the production and innovation of these new efficient diagnostic technologies including RDTs, molecular diagnostics, digital health among others. All these innovations do not only help the fight against malaria in affected nations, but it is also helps the worldwide campaign towards the eradication of the disease. Most of the funding and technical support comes from the United States government and other global partner organizations such as the Global Fund and USAID result in increased utilization of accurate diagnostic tools in malaria control programs globally.
• Second, the market’s dominate position is in North America because of the well-fixed health care system, high expenditures of health care, and a sound medical research environment. Clinical analysis of the market highlights specific and advanced diagnostic tools demand including PCR and LAMP in various clinical fields across the region. These technologies are becoming widely embraced in malaria mapping, antimalarial drug efficacy testing, and other epidemiologic investigations. Further, increasing number of private public partnerships along with the growing concerns towards global health security are anticipated to drive the position of North America again in the malaria diagnostics market. As the North American producers increase their operations across the malaria endemic countries, there will be increase in use of these diagnostic products hence the region’s continuous leadership in the market.

Active Key Players in the Malaria Diagnostics Market:

• Abbott Diagnostics (USA)
• Abbott Laboratories (USA)
• BD (Becton, Dickinson and Company) (USA)
• Bio-Rad Laboratories, Inc. (USA)
• Cepheid (USA)
• Chembio Diagnostics, Inc. (USA)
• Danaher Corporation (USA)
• F. Hoffmann-La Roche AG (Switzerland)
• Grifols, S.A. (Spain)
• Hologic, Inc. (USA)
• Medtronic (Ireland)
• Mérieux NutriSciences (France)
• Mylan N.V. (USA)
• Premier Medical Corporation (India)
• Roche Diagnostics (Switzerland)
• Siemens Healthineers (Germany)
• Sysmex Corporation (Japan)
• Thermo Fisher Scientific (USA)
• Other Active Players